Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galinpepimut-S + nivolumab
- Development stage
- Phase 1
- Lead developer
- SELLAS Life Sciences Group
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
Galinpepimut-S + nivolumab is a combination immunotherapy regimen under clinical investigation for the treatment of cancers expressing the Wilms Tumor 1 (WT1) antigen. Galinpepimut-S is a tetravalent peptide cancer vaccine targeting WT1, designed to stimulate both CD4+ and CD8+ T-cell responses against tumor cells overexpressing this antigen. Nivolumab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), thereby enhancing T-cell mediated anti-tumor immunity. The combination aims to potentiate immune responses by both priming tumor-specific T-cells (via galinpepimut-S) and relieving immune suppression in the tumor microenvironment (via PD-1 blockade with nivolumab). This approach has shown promising safety and immunogenicity profiles in early-phase trials for malignant pleural mesothelioma and ovarian cancer[4][7][8]. SELLAS Life Sciences Group develops galinpepimut-S; Bristol Myers Squibb develops/manufactures nivolumab.
- Other names
- WT1 vaccine + nivolumabGPS + nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on galinpepimut-S + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galinpepimut-S + nivolumab.